Friis Agar (M-FRIIS-X)

Description

Friis agar is specifically formulated for the cultivation of fastidious avian mycoplasmas and is supplemented with nicotinamide adenine dinucleotide (NAD⁺) to support the metabolic requirements of Mycoplasma synoviae. The medium contains phenol red as a pH indicator, which undergoes a colorimetric shift from red to yellow or purple in response to acidic or alkaline metabolic byproducts, thereby serving as a qualitative marker for mycoplasma growth.

To suppress non-mycoplasmal microbial contaminants, penicillin G is incorporated into the formulation, selectively inhibiting the proliferation of accompanying bacterial flora. Additionally, the supplementation of lipid components from yolk, including cholesterol and essential fatty acids, significantly enhances the growth performance of lipid-requiring strains—most notably Mycoplasma pneumoniae ATCC 23714—by facilitating membrane synthesis and metabolic activity under in vitro conditions.

Specifications

Application

FRIIS agar is recommended for the detection of non-avian mycoplasmas in pharmaceutical products, particularly in bulk vaccines, cell banks, and virus cultures.

Features

• Ready-to-use convenience — no further preparation steps are required.

• Pharmaceutical applications — suitable for biopharmaceuticals, vaccines, cell cultures, and virus cultures.

• Storage stability — can be stored at 2–8 °C for up to 6 months.

• Rapid detection — a colorimetric chart provides a convenient visual indication of early-stage mycoplasma proliferation.

• Optimized growth — the buffered system supports higher colony counts while reducing the risk of mycoplasma cell death.

• Enhanced visualization — a chromogenic reagent selectively stains mycoplasma, improving detection clarity and specificity under microscopy.

• Improved NAD⁺ stability — to prevent growth inhibition caused by NAD⁺ degradation at later stages, alternative NAD⁺ analogs are co-supplemented in the culture system.

Documents

M-FRIIS-X SDS